Raltegravir and Epivir drug interactions - a phase IV clinical study of FDA data

Summary:

Drug interactions are reported among people who take Raltegravir (raltegravir) and Epivir (lamivudine). Common drug interactions include amyloidosis among females and emotional distress among males.

The phase IV clinical study analyzes what interactions people have when they take Raltegravir and Epivir. It is created by eHealthMe based on reports of 40 people who take the same drugs from the FDA, and is updated regularly.

What is Raltegravir?

Raltegravir has active ingredients of raltegravir. eHealthMe is studying from 5,054 Raltegravir users. Check the latest studies of Raltegravir.

What is Epivir?

Epivir has active ingredients of lamivudine. It is often used in hiv infection. eHealthMe is studying from 16,870 Epivir users. Check the latest studies of Epivir.



On Jul, 21, 2026

40 people who take Raltegravir and Epivir together, and have interactions are studied.

Raltegravir and Epivir drug interactions.

What are the common drug interactions of Raltegravir and Epivir, by gender? *:

female:

  1. Amyloidosis (a tumour within which amyloid is produced)
  2. Anuria (failure of the kidneys to produce urine)
  3. Arthralgia (joint pain)
  4. Aspartate aminotransferase increased
  5. Blood alkaline phosphatase increased
  6. Bone density decreased
  7. Cardiac arrest
  8. Cardiac failure congestive
  9. Choking (mechanical obstruction of the flow of air from the environment into the lungs)
  10. Cough

male:

  1. Emotional distress
  2. Pain
  3. Campylobacter gastroenteritis (infection of gastrointestinal system)
  4. Dyslipidaemia (abnormal amount of lipids)
  5. Gastrointestinal haemorrhage (bleeding gastrointestinal tract)
  6. Haemoglobin decreased
  7. Haemorrhoids (a swollen vein or group of veins in the region of the anus)
  8. Herpes zoster
  9. Malaise (a feeling of general discomfort or uneasiness)
  10. Oropharyngeal discomfort (pain or irritation of oropharynx)

What are the common drug interactions of Raltegravir and Epivir, by age (0-1 to 60+)? *:

0-1:

n/a

2-9:

n/a

10-19:

n/a

20-29:

  1. Abdominal distension
  2. Anaemia (lack of blood)
  3. Atrioventricular block second degree (heart block second degree)
  4. Blood triglycerides increased
  5. Bradycardia (abnormally slow heart action)
  6. Campylobacter gastroenteritis (infection of gastrointestinal system)
  7. Dyslipidaemia (abnormal amount of lipids)
  8. Gastrointestinal haemorrhage (bleeding gastrointestinal tract)
  9. Haemoglobin decreased
  10. Haemorrhoids (a swollen vein or group of veins in the region of the anus)

30-39:

  1. Device expulsion
  2. Disseminated intravascular coagulation (systemic activation of blood coagulation)
  3. Immune thrombocytopenic purpura (destruction of blood platelets due to the presence of antiplatelet auto antibodies)
  4. Kaposi's sarcoma aids related (a tumour caused by human herpes virus associated with aids)
  5. Multi-organ failure (multisystem organ failure)
  6. Pancreatitis (inflammation of pancreas)
  7. Pleural effusion (water on the lungs)
  8. Seizure (abnormal excessive or synchronous neuronal activity in the brain)
  9. Amylase increased
  10. Death

40-49:

  1. Renal transplant
  2. Renal tubular disorder (disease of kidney tubules)
  3. Respiratory distress (difficulty in breathing)
  4. Thrombocytopenia (decrease of platelets in blood)
  5. Troponin increased
  6. Upper limb fracture
  7. Urinary incontinence (inability to control the flow of urine and involuntary urination)
  8. Vitamin d deficiency
  9. Vomiting
  10. Weight decreased

50-59:

  1. Anhedonia (inability to experience pleasure from activities usually found enjoyable)
  2. Anxiety
  3. Chronic kidney disease
  4. Emotional distress
  5. Pain
  6. Blood creatinine increased
  7. Decreased activity
  8. Fatigue (feeling of tiredness)
  9. Fear
  10. Osteopenia (a condition where bone mineral density is lower than normal)

60+:

  1. Renal failure (kidney dysfunction)
  2. Foot fracture
  3. Osteonecrosis (death of bone)
  4. Osteopenia (a condition where bone mineral density is lower than normal)
  5. Osteoporosis (bones weak and more likely to break)
  6. Pain
  7. Rib fracture
  8. Chills (felling of cold)
  9. Hypersensitivity
  10. Pancreas infection

What are the existing conditions these people have? *

  1. Hiv Infection: 38 people, 95.00%
  2. Anaemia (lack of blood): 7 people, 17.50%
  3. Pain: 7 people, 17.50%
  4. Gastroesophageal Reflux Disease (a condition in which stomach contents leak backward from the stomach into the oesophagus): 4 people, 10.00%
  5. Infection: 4 people, 10.00%
  6. Diarrhea: 4 people, 10.00%
  7. Haemorrhoids (a swollen vein or group of veins in the region of the anus): 4 people, 10.00%
  8. Abdominal Distension: 4 people, 10.00%
  9. Lower Gastrointestinal Haemorrhage (bleeding in the large intestine, rectum, or anus is called lower gi bleeding): 4 people, 10.00%
  10. Depression: 3 people, 7.50%

* Approximation only. Some reports may have incomplete information.

Do you take Raltegravir and Epivir?

- Personalize this study to your gender, age, symptoms and drugs
- Predict drug outcomes for up to one year with AI
- Get an AI agent to monitor your drugs continuously



Related studies:

Effectiveness of, side effects of, and alternative drugs to the 2 drugs:

Browse all drug interactions of Raltegravir and Epivir:

a b c d e f g h i j k l m n o p q r s t u v w x y z

Sub-studies by gender and age:

Female: 0-1 2-9 10-19 20-29 30-39 40-49 50-59 60+

Male: 0-1 2-9 10-19 20-29 30-39 40-49 50-59 60+

Browse all side effects of Raltegravir:

a b c d e f g h i j k l m n o p q r s t u v w x y z

Browse all side effects of Epivir:

a b c d e f g h i j k l m n o p q r s t u v w x y z

Browse all interactions between Raltegravir and drugs from A to Z:

a b c d e f g h i j k l m n o p q r s t u v w x y z

Browse all interactions between Epivir and drugs from A to Z:

a b c d e f g h i j k l m n o p q r s t u v w x y z

How the study uses the data?

The study uses data from the FDA. It is based on raltegravir and lamivudine (the active ingredients of Raltegravir and Epivir, respectively), and Raltegravir and Epivir (the brand names). Other drugs that have the same active ingredients (e.g. generic drugs) are not considered. Dosage of drugs is not considered in the study.

How to use the study?

DO NOT STOP MEDICATIONS without first consulting your doctor. If there are any serious or long term adverse effects discovered in the study, discuss the study with your doctor to ensure that proper medication management will be in place if applicable.

Who is eHealthMe?

With medical big data and proven AI/ML algorithms, eHealthMe provides a platform for everyone to run phase IV clinical trials. We study millions of patients and 5,000 more each day. Results of our real-world drug study have been referenced on 800+ peer-reviewed medical publications, including The Lancet, Mayo Clinic Proceedings, and Nature. Our analysis results are available to researchers, health care professionals, patients (testimonials), and software developers (open API).

WARNING, DISCLAIMER, USE FOR PUBLICATION

WARNING: Please DO NOT STOP MEDICATIONS without first consulting a physician since doing so could be hazardous to your health.

DISCLAIMER: All material available on eHealthMe.com is for informational purposes only, and is not a substitute for medical advice, diagnosis, or treatment provided by a qualified healthcare provider. All information is observation-only. Our phase IV clinical studies alone cannot establish cause-effect relationship. Different individuals may respond to medication in different ways. Every effort has been made to ensure that all information is accurate, up-to-date, and complete, but no guarantee is made to that effect. The use of the eHealthMe site and its content is at your own risk.

If you use this eHealthMe study on publication, please acknowledge it with a citation: study title, URL, accessed date.



Recent studies on eHealthMe: